The researchers engineered bacteriophages-tiny viruses that attack bacteria-to inject TB bacteria with a glowing, fluorescent-green protein.
The method must next undergo clinical trials, but it has potential as a valuable, time saving tool in rural African areas besieged by TB, explained the paper's senior author Graham Hatfull, chair and Eberly Family Professor of Biological Sciences in Pitt's School of Arts and Sciences.
Hatfull conducted the research with Professor William Jacobs Jr. of the Department of Microbiology and Immunology at the Albert Einstein College of Medicine of Yeshiva University in New York and Pitt postdoctoral fellow Mariana Piuri.
'A report from South Africa showed that the extensively drug-resistant TB strains can kill within 16 days, on average,' Hatfull said.
'In rural Africa, it takes too long to collect samples, send them off, do the test, and have the data sent back. Clinicians need rapid, relatively cheap, and simple methods for detecting TB and drug-resistant strains at the local clinic. This test provides a quick diagnosis so the patient can be isolated and treated.'
The group constructed bacteriophages specific to TB that have a green fluorescence protein (GFP) implanted in their genome. Bacteriophages spread by injecting their DNA into bacterial cells-in this case the GFP gene accompanies the DNA into the TB cell, causing the cell to glow. A clinician can detect the GFP's glow with equipment available at many clinics.
Besides quick diagnosis, the test also could be used to distinguish treatable TB strains from those that are drug resistant, a chore that can normally take months, Hatfull said. Hatfull and his colleagues treated M. tuberculosis with antibiotics at the same time the bacteriophages were introduced; the TB strains that were sensitive to antibiotics died, but the drug-resistant cells survived and continued to glow.
The group's research was funded as part of a major new research initiative from Howard Hughes Medical Institute (HHMI).
The institute announced March 19 that it will partner with South Africa's University of KwaZulu-Natal to establish an international research centre focused on the TB and HIV coepidemics in Africa, called KwaZulu-Natal Research Institute for TB-HIV. Jacobs will direct research into developing rapid and effective TB tests, one of the new institute's primary objectives. His work with Hatfull and Piuri was related to that effort.
For more information, visit www.hhmi.org
